Latest News
-
CAR T-Cell Immunotherapy Named Advance of the Year in Annual ASCO Report
A new and unique new way to treat cancer – CAR T-cell therapy – is poised to transform the outlook for children and adults with certain otherwise incurable cancers. The American Society of Clinical Oncology (ASCO) named this type of adoptive cell immunotherapy the Advance of the Year in its annual report. Released within the scope of the World... -
Medical College of Wisconsin: first successful treatment of CART patient and use of Miltenyi’s CliniMACS Prodigy®
The Medical College of Wisconsin has published a press release reporting on their first successfully treated CART patient and how they used Miltenyi’s CliniMACS Prodigy®. Physicians and researchers from the Medical College of Wisconsin (MCW), Froedtert Hospital, Children's Hospital of Wisconsin, and BloodCenter of Wisconsin have... -
First CARAT training course on “GMP-compliant CAR T cell manufacturing” completed
Just at the end of the first half of the CARAT project, a first one-week training course on “GMP-compliant CAR T cell manufacturing” took place on December 11-15, 2017at Miltenyi Biotec headquarters in Bergisch Gladbach, Germany. Five outstanding scientists from all over Europe with profound experience in the cell and gene therapy field were... -
New CAR T-Cell Therapy Approved by the FDA for the Treatment of Patients With Relapsed or Refractory Large B-Cell Lymphoma
In October 2017, the pharmaceutical company Kite announced that the U.S. Food and Drug Administration (FDA) has granted regular approval to Yescarta™, the first chimeric antigen receptor T cell (CAR T) therapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. This... -
Combating Leukaemia: German TV Broadcast on CAR T-Cell Therapy
The German regional TV station WDR broadcasted a contribution on December 12, 2017 on CAR T-cells focusing on the benefits for patients but mentioning also the high costs of the treatment and the severe side effects. One of the interview partners is Prof Klaus Cichutek, Head of Paul-Ehrlich-Institut (PEI) who is also a partner in CARAT. CAR... -
Personalised Cancer Treatment: Successful Project Meeting of H2020 Project CARAT
It is almost half-time in CARAT and the 2nd Progress Meeting hosted by partner INSERM in Paris on October 10-11, 2017 took place just at the right time with the news about the first gene therapy approved by the US Food and Drug Administration (FDA) still being fresh. Additionally, PEI’s review in the EMBO Journal in which they evaluated 200... -
-
First CAR T-cell gene therapy approved in the USA
On August 30,2017, the US Food and Drug Administration (FDA) made the first gene therapy available in the United States: They approved Kymriah, a cell-based gene therapy, for the treatment of patients up to the age of 25 with acute lymphoblastic leukemia (ALL). The CAR T-cells potential has been detected already 20 years ago and research in the...